Anti-C35 antibodies for treating cancer
AssigneeVaccinex, Inc.
InventorsElizabeth E. Evans, Mark J. Paris, Deepak M. Sahasrabudhe, Maurice Zauderer, Ernest S. Smith
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and a chemotherapeutic agent. In some preferred embodiments, two C35 antibodies are administered with a chemotherapeutic agent. The present invention is further directed to C35 antibodies useful in these methods.
Claims53
A method of killing cancer cells that express C35, the method comprising administering to said cells (a) a first C35 antibody or antigen binding fragment thereof that specifically binds C35;
- (b) a second C35 antibody or antigen binding fragment thereof that specifically binds C35;
- and (c) a therapeutic agent.
An isolated antibody or antigen-binding fragment thereof which specifically binds to the same C35 epitope as the reference antibody MAb 163.
28-48. (canceled)
50-111. (canceled)
An isolated polynucleotide comprising a nucleic acid sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the MAb 163 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35.
113-117. (canceled)
119-125. (canceled)
127-149. (canceled)
(canceled)
An isolated polypeptide comprising an immunoglobulin heavy chain variable region (VH), wherein the CDR1, CDR2, and CDR3 regions of said VH are identical respectively, except for fewer than 10 amino acid substitutions, to reference heavy chain CDR1, CDR2, and CDR3 sequences consisting of SEQ ID NO:63, SEQ ID NO:64, and SEQ ID NO:65, and wherein an antibody or antigen-binding fragment thereof comprising said VH specifically binds to C35.
155-180. (canceled)
182-198. (canceled)
201-202. (canceled)
A composition comprising:
- (a) a first C35 antibody that specifically binds to C35;
- (b) a second C35 antibody that specifically binds to C35;
- and (c) a therapeutic agent.
204-209. (canceled)
211-213. (canceled)
An isolated antibody or antigen binding fragment thereof comprising at least one, two, three, four, five or six CDRs of the MAb 163 monoclonal antibody, wherein said antibody or fragment specifically binds C35.
215-220. (canceled)
Dependencies are inferred from the claim text.